维瓦尼医疗获得澳大利亚首次对人类进行GLP-1 (exenatide) 植入物治疗肥胖的临床试验的批准. Vivani Medical receives approval for Australia's first-in-human clinical trial of GLP-1 (exenatide) implant for obesity treatment.

维瓦尼医疗公司已获得批准在澳大利亚进行首次人体临床试验,用于治疗肥胖的GLP-1 (exenatide) 植入物. Vivani Medical has received approval to conduct a first-in-human clinical trial in Australia for its GLP-1 (exenatide) implant aimed at treating obesity. 这项名为LIBERATE-1的试验将评估与半谷氨酸相比的植入物的安全性和有效性,并有可能每两年一次使用. The trial, named LIBERATE-1, will assess the implant's safety and efficacy compared to semaglutide, with the possibility of biannual administration. 审判定于2024年底开始,预计到2025年会有数据,这可能有助于包括美国在内的其他区域提交监管报告。 The trial is set to begin in late 2024, with data expected by 2025, which may aid regulatory submissions in other regions, including the U.S.